Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M705200200 on July 10, 2007

J. Biol. Chem., Vol. 282, Issue 37, 26746-26753, September 14, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/37/26746    most recent
M705200200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Athanasopoulos, A. N.
Right arrow Articles by Chavakis, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Athanasopoulos, A. N.
Right arrow Articles by Chavakis, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Vascular Endothelial Growth Factor (VEGF)-induced Up-regulation of CCN1 in Osteoblasts Mediates Proangiogenic Activities in Endothelial Cells and Promotes Fracture Healing*

Athanasios N. Athanasopoulos{ddagger}1, Darius Schneider{ddagger}1, Tanja Keiper{ddagger}, Volker Alt§, Usha R. Pendurthi, Ute M. Liegibel{ddagger}, Ulrike Sommer{ddagger}, Peter P. Nawroth{ddagger}, Christian Kasperk{ddagger}, and Triantafyllos Chavakis{ddagger}||2

From the {ddagger}Department of Internal Medicine I, University Heidelberg, D-69120 Heidelberg, the §Department of Trauma Surgery, University Hospital Giessen-Marburg, D-35385 Giessen, Germany, the Biomedical Research Division, The University of Texas Health Center at Tyler, Tyler, Texas, and the ||Experimental Immunology Branch (EIB), NCI, National Institutes of Health, Bethesda, Maryland 20992

Received for publication, June 25, 2007 , and in revised form, July 9, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Angiogenesis is indispensable during fracture repair, and vascular endothelial growth factor (VEGF) is critical in this process. CCN1 (CYR61) is an extracellular matrix signaling molecule that has been implicated in neovascularization through its interactions with several endothelial integrin receptors. CCN1 has been shown to be up-regulated during the reparative phase of fracture healing; however, the role of CCN1 therein remains unclear. Here, the regulation of CCN1 expression in osteoblasts and the functional consequences thereof were studied. Stimulation of osteoblasts with VEGF resulted in a dose- and time-dependent up-regulation of CCN1 mRNA and protein. An up-regulation of both cell surface-associated CCN1 as well as extracellular matrix-associated CCN1 in osteoblasts was found. The supernatant of VEGF-prestimulated osteoblasts was chemotactic for endothelial cells, increasing their migration and stimulated capillary-like sprout formation. These effects could be attributed to the presence of CCN1 in the osteoblast supernatant as they were prevented by an antibody against CCN1 or by small interfering RNA-mediated knockdown of osteoblast CCN1. Moreover, the supernatant of VEGF-prestimulated osteoblasts induced angiogenesis in Matrigel plugs in vivo in a CCN1-dependent manner. In addition, blockade of CCN1 prevented bone fracture healing in mice. Taken together, the present work demonstrates a potential paracrine loop consisting of the VEGF-mediated up-regulation of CCN1 in osteoblasts that attracts endothelial cells and promotes angiogenesis. Such a loop could be operative during fracture healing.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Angiogenesis, the development of a microvascular network, is a strictly regulated process that is essential during embryonic development and healing mechanisms (1, 2). During bone growth, vascular structures invade the growth plate regions of the bone, providing a conduit for the entry of chondroclasts and osteoclasts that are involved in resorptive processes, whereas following bone injury, angiogenesis is transiently stimulated to promote repair mechanisms (3–5). Fracture repair is a multistep process involving migration, proliferation, and differentiation of several cell types such as endothelial cells, fibroblasts, chondroblasts, osteoblasts, and osteoclasts. Neovascularization in fracture repair is thought to be dependent on the functional cross-talk between bone-forming osteoblasts and endothelial cells within the bone microenvironment (6). However, although it was recognized very early that osteoblasts and osteoprogenitor cells are often located adjacent to endothelial cells in blood vessels at sites of new bone formation (7–9), it is not yet defined how osteoblasts may regulate angiogenesis-related endothelial cell functions.

Among a variety of proangiogenic growth factors, the vascular endothelial growth factor (VEGF)3 (2) plays a pivotal role in bone remodeling and healing. VEGF is produced by many cells in the bone environment and stimulates the invasion of new blood vessels into the cartilage, thereby playing a crucial role in regulating resorption of cartilage and bone formation (10). In the early stages of bone repair, large amounts of active VEGF are found in the fracture hematoma (11). VEGF is involved in conversion of the soft, cartilaginous callus to a hard, bony callus during fracture repair (12). Furthermore, VEGF has chemotactic effects on osteoblasts and may directly enhance their activity in vitro (13) or may indirectly induce their proliferation and differentiation by stimulating endothelial cells to produce osteoanabolic growth factors (14).

Emerging evidence points to a role of the CCN (CYR61, CTGF, Nov) family, comprising six members in humans, in both angiogenesis and osteogenesis. These proteins are secreted, extracellular matrix (ECM)-associated proteins that regulate cell adhesion, migration, differentiation, and survival (15). CCN1 (CYR61) is a cysteine-rich, heparin-binding protein, associated with both the ECM and the cell surface (16), which acts as an atypical non-Arg-Gly-Asp-containing ligand of integrin receptors of the beta1- and {alpha}v-family. In particular, CCN1 promotes endothelial cell migration, survival, and tubule formation in an {alpha}vbeta3-integrin-dependent manner (17). In addition to stimulating angiogenesis (18), CCN1 is implicated in chondrogenesis (19, 20). Interestingly, CCN1 expression is increased in the callus and the newly formed osteoid during the reparative phase of fracture healing (21); however, the role of CCN1 in this newly formed osteoid remains unclear. In particular, whether osteoblast-derived CCN1 may directly affect angiogenic functions of the endothelium has not been addressed yet.

These observations prompted us to investigate how VEGF and CCN1 could act in concert to link osteoblast and endothelial cell functions in the context of bone angiogenesis. The present study demonstrates a potential paracrine loop consisting of the VEGF-mediated up-regulation of CCN1 in osteoblasts that attracts vascular endothelial cells and promotes angiogenesis with potential implications in fracture healing.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—The following reagents were provided from the following sources. Platelet-derived growth factor (PDGF) AB, VEGF 165, transforming growth factor-beta1 (TGF-beta) were from R&D Systems (Wiesbaden, Germany); recombinant CCN1 protein was previously described (22) as well as purchased from Abnova (Taipei, Taiwan). Rabbit polyclonal antibody against human CCN1 and control rabbit IgG were from Santa Cruz Biotechnology (Heidelberg, Germany), whereas rabbit anti-CCN2 (connective tissue growth factor, CTGF) was from Abcam (Cambridge, MA), respectively. The polyclonal anti human CCN1 from rabbit was previously described (22). Fibrinogen and fibronectin and antibody to human actin were from Sigma-Aldrich (Munich, Germany); blocking monoclonal antibody LM609 against {alpha}v-integrin and blocking monoclonal antibody against beta1-integrin (6S6) were from Chemicon (Hofheim, Germany).

Cell Culture—Human umbilical vein endothelial cells (HUVEC) were from Promocell (Heidelberg, Germany) and cultured as described by the supplier. HUVEC were used in low passages (up to the fourth passage). Primary human osteoblastic cells were obtained from femoral bone biopsies of healthy adults (23) and cultivated as described previously (24).

Generation of Osteoblast-conditioned Supernatant—Primary human osteoblastic cells were grown to confluency in 6-well plates, washed one time with PBS, and starved for 12 h in serum free Dulbecco's modified Eagle's medium (DMEM) low glucose (Invitrogen, Karlsruhe, Germany). Cells were then washed and incubated for an additional 1 h in DMEM 0.2% (v/v) fetal calf serum, in the presence or absence of 20 ng/ml VEGF, after which the medium was again changed to DMEM 0.2% fetal calf serum. After 6 h, the supernatant was collected and used in cell migration and the in vitro angiogenesis assay. For in vivo angiogenesis, supernatant was concentrated using a 30-kDa cut-off Amicon ultracentrifugal filter device (Millipore, Schwalbach, Germany).

siRNA-mediated Knockdown of CCN1 in Osteoblasts—For transfections, a chemically synthesized duplex siRNA directed against human CCN1 or a non-targeting control siRNA (Dharmacon, Chicago, IL) was engaged. siRNAs were transfected at a concentration of 100 nM using HiPerfect transfection reagent (Qiagen, Valencia, CA), as described (25). 48 h after transfection, cells were stimulated with VEGF, and the osteoblast-conditioned supernatants were collected as described above. CCN1 in the supernatants from non-transfected osteoblasts, from osteoblasts transfected with control siRNA, or from osteoblasts transfected with specific CCN1 siRNA was assessed by Western blot analysis.

Extracellular Matrix Preparation of Osteoblasts—ECM preparation was performed according to our previously described protocol (26). Briefly, primary human osteoblasts were grown to confluency in 48-well plates and washed three times with PBS containing 2% (w/v) bovine serum albumin and 1 mmol/liter CaCl2. Cells were removed with PBS containing 0.5% (w/v) Triton X-100 for 15 min followed by incubation with 0.5% (w/v) Triton-X100 and 0.1 mol/liter NH3 for another 15 min at 22 °C. Finally, wells were washed with PBS and blocked with PBS containing 3% (w/v) bovine serum albumin.

Cell Migration Assay—Migration of endothelial cells was tested using Transwell membranes (8-µm pore size and 6.5-mm diameter) in 24-well plates (Corning Costar), as described previously (27). The membranes were coated with fibrinogen or fibronectin (each at 10 µg/ml) in PBS for 16 h at 4 °C, washed, and air-dried before use. After gentle trypsinization, the cells were resuspended in DMEM containing 0.2% (v/v) fetal calf serum, and 100 µl of cell suspension at a density of 106/ml was added to the top chamber. Stimuli were added to the lower wells. Each treatment was performed in quadruplicates. After incubation of plates at 37 °C for 6 h, the number of migrated cells in the lower compartment was estimated with a cell counter (CASY counter, Schärfe System, Reutlingen, Germany).

In Vitro Angiogenesis Assay—In vitro angiogenesis in fibrin gels was quantitated using endothelial cell spheroids as described previously (28, 29). Briefly, spheroids containing ~750 cells were generated overnight, after which they were added to fibrin gels. Fibrin gels were prepared by mixing 750 µl of a solution containing 1.8 mg/ml fibrinogen in PBS with thrombin (0.65 units/ml). The spheroid-containing gel was allowed to polymerize for 30 min. Then, another 750 µlof serum-free medium with the corresponding test substance or supernatant from osteoblasts was added without or together with competitors, the plates were laid on top of the gel, and the spheroids were incubated for an additional 48 h at 37 °C, 5% CO2, and 100% humidity. Spheroids were evaluated microscopically, and sprout formation was expressed as sprouting spheroids/total spheroids.

Matrigel Plug Assay—After thawing on ice, Matrigel (BD Biosciences) containing 30 IU/ml heparin (Liquemin, Roche Applied Science, Mannheim, Germany), in the absence or presence of VEGF or recombinant CCN1 (100 ng/ml each), and supernatant from prestimulated or non-stimulated osteoblasts, without or with competitors, in a total volume of 400 µl was injected subcutaneously into the laterodorsal abdominal region of 8-week-old male C57Bl/6 mice. The Matrigel samples were recovered 5 days after implantation for photo documentation. To quantitate neovascularization the hemoglobin concentration in Matrigel, homogentisates were measured as described (29, 30).

Cell ELISA and Matrix ELISA—Cell and matrix ELISA were performed for the detection of CCN1 in primary human osteoblasts and in their ECM. Briefly, osteoblasts were grown to confluency on 96-well plates. Thereafter, cells were washed and incubated in the absence or presence of stimuli in 0.2% fetal calf serum-containing medium for different time periods at 37 °C, as indicated in the figure legends. Following incubation, cells were washed twice with PBS, fixed with methanol/acetone (1:1), and blocked with PBS containing 3% bovine serum albumin for 1 h at 22°Cand then incubated with the first antibody (against CCN1, dilution 1:1000) in Tris-buffered saline containing 0.3% bovine serum albumin, 0.05% Tween 20 followed by the addition of appropriate secondary peroxidase-conjugated antibody and the substrate 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS). Total binding was quantitated at 405 nm, and nonspecific binding (binding of the secondary antibody to wells, in which the first antibody was omitted) was used as blank and was subtracted to calculate specific binding.

Reverse Transcription-PCR—Total RNA was extracted from cultured primary human osteoblasts using the RNeasy Mini Kit (Qiagen, Hilden, Germany) and digested with RNase-Free DNase (Qiagen, Hilden, Germany) to remove any contaminating genomic DNA. cDNA synthesis from total RNA was performed by the first strand cDNA synthesis kit for reverse transcription-PCR (Roche Diagnostics GmbH) according to the manufacturer's protocol. cDNA synthesis from total RNA was performed with avian myeloblastosis virus reverse transcriptase (Roche Diagnostics GmbH). To detect the expression of CCN1 and glyceraldehyde-3-phosphate dehydrogenase in primary human osteoblasts, the cDNA was used as a template for a normal PCR-reaction using primers specific for either CCN1 or glyceraldehyde-3-phosphate dehydrogenase, and it was incubated with Taq DNA polymerase (MBI-Fermentas, St. Leon-Rot, Germany) and the following primers: for CCN1, 5'-gcg ctc tcc acc tgc ccc-3' and 5'-aac tcc acc tcg gag gca-3'; and for glyceraldehyde-3-phosphate dehydrogenase, 5'-cca ccc atg gca aat tcc atg gca-3' and 5'-tct aga cgc cag gtc agg tcc acc-3'. All primers were synthesized by MWG-Biotech (Munich, Germany) and were of high purity salt-free quality. The polymerase was activated (3 min at 95 °C), and then up to 30 cycles (1 min at 95 °C, 1 min at 55 °C, 2 min at 72 °C) were performed on an MWG Primus 25 thermocycler. After the last cycle, all samples were incubated for an additional 10 min at 72 °C.

Bone Fracture Healing—Bone fractures were generated as described previously (31). 10-week-old female mice were used in each group. Briefly, on day 0, an anterior knee incision was made under general anesthesia with xylazine (0.2 mg/10 g of body weight, Bayer Leverkusen, Germany) and ketamine (0.5 mg/10 g of body weight, Sankyo, Osaka, Japan). A transverse osteotomy was then performed at the middle of the tibia with a bone saw (Volvere GX, NSK Nakanishi, Japan). Fractured bones were repositioned and stabilized by inserting the inner pin of a 23-gauge spinal needle intramedullary. Bone radiographs were taken by using a volumetric-computer tomography system (Siemens). Mice were treated with intraperitoneal injections of anti-CCN1 or control antibody (50 µg/mouse) at days 1, 2, 3, 5, 7, and 10. The fracture gap was visualized and measured at days 4 and 14 by the use of radiograph postprocessing software (ChiliPacs®, Chili, Heidelberg, Germany).


Figure 1
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 1.
VEGF induces CCN1 up-regulation in osteoblasts. A, influence on CCN1 mRNA expression by TGF-beta (20 ng/ml; 2 h; gray bar) and VEGF (20 ng/ml; 2 h; black bar) as indicated. CCN1 mRNA expression is presented as the percentage of control (in the absence of stimuli). B and C, the expression of CCN1 protein on the cell surface (B) and on the extracellular matrix (C) of osteoblasts was studied in the absence or presence of PDGF or VEGF (for 12 h), as indicated. Data are mean ± S.D. ns, not significant; **, p < 0.01.

 
Statistical Analysis—Data were compared using the Student's t test and analysis of variance as appropriate; p values of <0.05 were regarded as significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
VEGF Increases Expression of CCN1 mRNA and Protein in Osteoblasts—CCN1 protein is present at low or undetectable levels in quiescent cells but is rapidly synthesized upon stimulation (32). Upon synthesis, CCN1 may be detected on the cell surface as well as it may be secreted extracellularly and may associate with ECM (16, 33). We therefore studied the regulation of expression of CCN1 in primary osteoblasts. Stimulation of osteoblasts with VEGF resulted in a significant up-regulation of both CCN1 mRNA and protein (Fig. 1, A and B), whereas PDGF or TGF-beta hardly affected CCN1 expression in osteoblasts. Up-regulated CCN1 was both detected in the cell surface (Fig. 1B) as well as associated with ECM preparations of the osteoblasts (Fig. 1C). In addition, the VEGF-mediated up-regulation of CCN1 was dose-dependent and time-dependent (Fig. 2, A and B). Interestingly, during the time course of osteoblast stimulation by VEGF, the pattern of up-regulation of ECM-associated CCN1 paralleled that of surface-associated CCN1.


Figure 2
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 2.
VEGF induces CCN1 expression in a dose- and time-dependent manner. A, CCN1 protein expression on the cell surface and extracellular matrix of osteoblasts was studied in the absence or presence of increasing concentrations of VEGF (for 12 h). B, time course of the effect of VEGF (20 ng/ml) on CCN1 protein expression on the cell surface and extracellular matrix of osteoblasts. CCN1 protein expression in osteoblasts is presented as the percentage of control (CCN1 expression in the absence of competitor represents the 100% control). Data are mean ± S.D. of a typical experiment; similar results were obtained in three separate experiments.

 
Osteoblast-derived CCN1 Promotes Endothelial Cell Migration—CCN1 has been reported to stimulate adhesive and migratory endothelial cell functions (17, 34). Consistently, recombinant CCN1 stimulated the migration of HUVEC toward fibronectin or fibrinogen in a beta1-integrin- and {alpha}v-integrin-dependent manner, respectively, as observed by inhibition studies with specific blocking antibodies against these integrins (data not shown). The promigratory effect of CCN1 was comparable with the effect of VEGF (Fig. 3A). The up-regulation of CCN1 in osteoblasts by VEGF, as observed above, prompted us to investigate whether osteoblasts might exert proangiogenic activities. In particular, we studied whether the conditioned medium of VEGF-stimulated osteoblasts could also induce endothelial cell migration. The supernatant of osteoblasts prestimulated in the presence of VEGF promoted the migration of endothelial cells toward both fibronectin and fibrinogen by 2–3-fold (Fig. 3, B and C). The supernatant of non-stimulated osteoblasts only marginally promoted HUVEC migration (Fig. 3, B and C). Moreover, HUVEC migration induced by the conditioned medium of VEGF-prestimulated osteoblasts was abolished in the presence of an antibody against CCN1 (Fig. 3, B and C), whereas a control antibody or an antibody to another CCN family member, CTGF, were not effective at all.


Figure 3
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 3.
Osteoblast-derived CCN1 promotes endothelial migration. A, migration of HUVEC toward fibronectin (filled bars) or fibrinogen (open bars) (each 10 µg/ml) is shown in the absence (–) or presence of VEGF (100 ng/ml) or CCN1 (100 ng/ml) in the lower well. Data are mean ± S.E. of three experiments. *, p < 0.05 as compared with control (migration toward fibrinogen in the absence of stimulus); #, p < 0.02 as compared with control (migration toward fibronectin in the absence of stimulus). B and C, migration of HUVEC toward fibrinogen (B) and fibronectin (C) is shown in the absence of any stimulus (open bar) or in the presence of VEGF (100 ng/ml, filled bar), the supernatant from not prestimulated osteoblasts (OSN, gray bars), or the supernatant from VEGF-stimulated osteoblasts (VEGF-OSN, hatched bars) or, without or with anti-CCN1, anti-CTGF, or control antibody (con-IgG) (each 20 µg/ml). Data are mean ± S.E. of three experiments. *, p < 0.05; **, p < 0.01.

 
To provide further evidence for the specific role of CCN1 as the pro-migratory moiety of the osteoblast supernatant, we employed an alternative way to inhibit CCN1 by engaging siRNA-mediated knockdown. Significant down-regulation of CCN1 by 40–50% was achieved in cells transfected with siRNA-targeting CCN1 but not with control non-targeting siRNA (Fig. 4A). As demonstrated in Fig. 4, B and C, conditioned medium from VEGF-stimulated osteoblasts transfected with siRNA against CCN1 had reduced capacity of promoting endothelial cell migration toward fibrinogen or fibronectin, as compared with conditioned medium from VEGF-stimulated non-transfected osteoblasts or osteoblasts transfected with control non-targeting siRNA. Together, these data indicate that the pro-migratory effect of the osteoblast supernatant could be specifically attributed to the presence of CCN1 therein.


Figure 4
View larger version (18K):
[in this window]
[in a new window]

  		FIGURE 4.
A, the levels of CCN1 in supernatants from VEGF-stimulated osteoblasts are shown. Supernatants of non-transfected (–) osteoblasts, osteoblasts transfected with control non-targeting siRNA (CON-siRNA), or osteoblasts transfected with specific CCN1 siRNA were assessed for their CCN1 levels by performing Western blot analysis. Data are expressed as the percentage of control (the CCN1 levels in supernatants from VEGF-stimulated non-transfected osteoblasts represent the 100% control). Significant down-regulation of CCN1 was observed only in osteoblasts transfected with specific CCN1 siRNA. ns, not significant, **, p < 0.01 as compared with control. B and C, migration of HUVEC toward fibrinogen (B) or fibronectin (C) (each 10 µg/ml) is shown in the absence (open bar) or presence of supernatant from VEGF-stimulated osteoblasts (VEGF-OSN, filled bars) in the lower well. Supernatants of non-transfected (–) osteoblasts, osteoblasts transfected with control non-targeting siRNA, or osteoblasts transfected with specific CCN1 siRNA were used. Data are mean ± S.E. of three experiments. ns, not significant; *, p < 0.05; **, p < 0.01.

 


Figure 5
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 5.
Effect of osteoblast-derived CCN1 on in vitro capillary sprout formation. HUVEC were incubated for 24 h in the absence (open bar) or presence of supernatant from not stimulated osteoblasts (OSN; gray bars) or from VEGF-prestimulated osteoblasts (VEGF-OSN; hatched bars) without or together with anti-CCN1, anti-CTGF, or control antibody (con-IgG) (each 20 µg/ml). Capillary-like tube formation is expressed relative to control, which is represented as sprout formation in the absence of any stimulus or competitor. Data are mean ± S.D. of three experiments. *, p < 0.05; **, p < 0.01.

 
Induction of Capillary Sprout Formation in Vitro by Osteoblast-derived CCN1—Above, we demonstrated that supernatant from VEGF-stimulated osteoblasts and especially CCN1 therein may promote migration of endothelial cells in vitro,a process essential for neovascularization. Therefore, we next examined the role of osteoblast-derived supernatant in a more complex in vitro assay that simulates angiogenesis. Capillary-like tube formation in three-dimensional fibrin gels depends on the invasive and migratory potential of endothelial cells. In this system, the supernatant of VEGF-prestimulated osteoblasts increased the number of capillary-like endothelial sprouts by 2-fold, whereas the supernatant of non-stimulated osteoblasts had no effect at all (Fig. 5). Interestingly, an antibody against CCN1 prevented the capillary-like sprout formation induced by the supernatant of VEGF-stimulated osteoblasts, whereas control antibody or antibody to CTGF failed to inhibit sprout formation (Fig. 5). These findings indicate that the VEGF-mediated up-regulation of CCN1 in osteoblasts accounts, at least partially, for the pro-angiogenic activity in the supernatant of osteoblasts.

Osteoblast-derived CCN1 Stimulates Angiogenesis in Vivo—The pro-angiogenic activity of CCN1 and the supernatant from VEGF-stimulated osteoblasts was then investigated in vivo using the Matrigel plug neovascularization assay. Matrigel was injected subcutaneously into the laterodorsal abdominal region of mice in the absence or presence of recombinant VEGF or recombinant CCN1 or the supernatant from osteoblasts that were prestimulated in the absence or presence of VEGF. The Matrigel matrixes were recovered 5 days later for analysis. The degree of neovascularization was quantified by determining the hemoglobin concentration in the Matrigel matrixes. Recombinant CCN1 induced a strong angiogenic response comparable with VEGF. Furthermore, the supernatant derived from VEGF-prestimulated osteoblasts induced neovascularization in the Matrigel plugs, whereas neovascularization was only weakly induced by the supernatant of non-stimulated osteoblasts (Fig. 6). Interestingly, the supernatant derived from VEGF-stimulated osteoblasts induced an almost maximal angiogenic response in the Matrigel plug assay that was comparable with the effect of recombinant VEGF (Fig. 6). Moreover, the use of an antibody against CCN1 prevented angiogenesis in response to the supernatant from VEGF-stimulated osteoblasts, whereas control antibody or antibody to CTGF were not effective at all (Fig. 6; data with anti-CTGF not shown). The specificity of the inhibitory effect of the antibody to CCN1 was also demonstrated by the fact that anti-CCN1 did not affect angiogenesis directly induced by recombinant VEGF (Fig. 6). These data indicate that the angiogenic effect of the osteoblast supernatant could be attributed to the presence of CCN1 therein. Taken together, these data indicate that VEGF up-regulates CCN1 in osteoblasts, which then promotes angiogenesis in vitro and in vivo.


Figure 6
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 6.
Effect of osteoblast-derived CCN1 on in vivo angiogenesis. Neovascularization in the Matrigel plug assay was studied in the absence (buffer; open bar) or presence of VEGF (100 ng/ml; filled bars), recombinant CCN1 (100 ng/ml; dotted bars), the supernatant from not stimulated osteoblasts (OSN; gray bars), or VEGF-prestimulated osteoblasts (VEGF-OSN; hatched bars) without (–) or together with anti-CCN1 or control antibody (con-IgG) (each 20 µg/ml). The quantitation of neovascularization in the Matrigel matrixes was performed by measuring their hemoglobin concentration. Hemoglobin concentration was expressed as mg of hemoglobin/g of wet tissue. Data are expressed as the percentage of the maximum (VEGF treatment in the absence of competitors). Data are mean ± S.D. of three experiments. ns, not significant; **, p < 0.01.

 
CCN1 Promotes Bone Fracture Healing in Vivo—The data obtained so far indicated that CCN1 may participate in angiogenesis in the context of bone fracture healing. To provide direct evidence for that, we studied the effect of CCN1 blockade in bone fracture healing model in mice. A transverse osteotomy was performed at the middle of the tibia, and fracture healing was followed by bone radiographs taken with a volumetric-CT system at days 4 and 14 after the fracture (31). By analyzing the size of the fracture gap, we found that fracture healing at day 14 was significantly inhibited by anti-CCN1, whereas no effect of the control antibody was observed (Fig. 7). Together, these data suggest that CCN1 is involved in fracture healing.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Neovascularization is indispensable for bone fracture repair, during which a coordinated cross-talk between osteoblasts and endothelial cells needs to take place in the local microenvironment (3–6). Here, we have demonstrated that VEGF and CCN1 may synergize in coupling osteoblasts and endothelial cells functionally. In particular, we found that osteoblast CCN1 expression is stimulated by VEGF, and this osteoblast-derived CCN1 may in turn stimulate proangiogenic functions in the endothelial cells, such as migration or capillary-like sprout formation. Additionally, we observed that osteoblast-derived CCN1 promotes angiogenesis in vivo, as well as fracture healing. Thus, our present findings point to a potential paracrine loop that may be important in the communication between osteoblasts and endothelial cells during bone angiogenesis.


Figure 7
View larger version (41K):
[in this window]
[in a new window]

  		FIGURE 7.
CCN1 blockade impairs fracture healing. A, representative vCT images of tibial fractures 14 days after fracture. The arrows indicate the fracture gap. In the upper panel (control antibody (con-IgG) treatment), the fracture is almost completely healed, as indicated by the fact that the fracture gap is almost not measurable. In the lower panel (anti-CCN1 treatment), the fracture gap is still present. B, comparison of the fracture gap (in mm) at day 14 from control antibody treated (open bars) and anti-CCN1 treated (filled bars) mice. Data are mean ± S.D. (n = 3 mice/group). **, p < 0.01.

 
Among several growth factors that are up-regulated during skeletal development and induced upon injury, a major role has been attributed to VEGF for bone development and fracture repair (4, 12, 35, 36). Unequivocally, VEGF is crucial in promoting neovascularization; however, VEGF may also be a key regulator in growth plate morphogenesis and cartilage remodeling. In vivo, VEGF blockade resulted not only in the vascular ablation in the growth plate but also in impaired trabecular bone formation (10), whereas a cartilage-specific VEGF deletion was accompanied by a similar phenotype (38). Moreover, VEGF inhibition in mice disrupted repair of femoral fractures and cortical bone defects (12). VEGF also directly regulates the proliferation and migration of osteoblasts that express both VEGF receptors, and systemic inhibition in mice led to a reduction in the osteoblast numbers at the growth plates (4, 39, 40). Over and above these direct effects of VEGF on osteoblasts and endothelial cells, VEGF may also have "indirect" paracrine effects that orchestrate osteogenesis and angiogenesis. The here described paracrine loop mediated by the proangiogenic activities of osteoblast-derived CCN1 that is induced by VEGF may represent such a pathway for the amplification of the proangiogenic and osteoanabolic effects of VEGF.

High CCN1 protein levels have been detected throughout the reparative phase of the callus, particularly in proliferating chondrocytes, osteoblasts, as well as within the newly formed osteoid (21). In fracture callus, VEGF expression is very early and tightly linked to the appearance of osteoblasts (41), and both VEGF and CCN1 have been found to co-localize in the edematous area of osteonecrosis (42). Thus, our present findings suggest that VEGF-stimulated osteoblasts may represent a major source for the increased CCN1, and the functional interplay between VEGF and CCN1 shown here is consistent with these previous histological data. Additionally, although we cannot exclude that another proangiogenic moiety besides CCN1 is induced in osteoblasts by VEGF, CCN1 inhibition almost abolished the proangiogenic activities of the supernatant from VEGF-stimulated osteoblasts. As demonstrated here, CCN1 unequivocally mediates the proangiogenic activities of osteoblasts as well as fracture healing. Although these two functions of CCN1 are likely to be intimately linked with each other, it is still conceivable that the role of CCN1 in fracture healing may be the result of further not yet identified actions of CCN1 separable from its proangiogenic activities.

Interestingly, CCN1-deficient mice displayed embryonic lethality due to placental vascular insufficiency and reduced vessel integrity. This effect was attributed to the reduced expression of VEGF-C in the allantoic mesoderm of CCN1-deficient mice (43). In addition, CCN1 may stimulate the expression of proangiogenic growth factors including VEGF or the basic fibroblast growth factor, as well as metalloproteases in different cells (44). Thus, the regulation of CCN1 by VEGF in osteoblasts, as presented here, may be more complex. The intriguing observation that VEGF up-regulates CCN1, and vice versa, strengthens the hypothesis that a paracrine loop exists between CCN1 and VEGF that may regulate angiogenesis in several (patho-)physiological processes including fracture healing.

The up-regulated osteoblast-derived CCN1 was associated with both the cell surface and the extracellular matrix of the osteoblasts. This extracellular matrix-associated CCN1 in the bone microenvironement may be released by proteases such as plasmin, thereby allowing it to act onto endothelial cells at more distant sites. In fact, the plasmin-mediated cleavage of CCN1 from the matrix of tumor cells was recently demonstrated (22).

The signaling intermediates responsible for the VEGF-induced up-regulation of CCN1 in osteoblasts were not addressed in this study. Recently, CCN1 expression in osteoblasts was demonstrated to be regulated by the Wnt/beta-catenin signaling pathway (45). Moreover, in bladder smooth muscle cells, CCN1 overexpression increased the expression of VEGF (37). Whether CCN1 may also induce VEGF expression in osteoblasts, which would implicate the existence of a VEGF-CCN1 autocrine loop in these cells, is worth addressing in a future study. Nevertheless, our present findings provide clear evidence that VEGF and CCN1 cooperate to mediate a crosstalk between osteoblasts and endothelial cells, which may be operative in bone angiogenesis and fracture healing.


   FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Both authors contributed equally to the work. Back

2 To whom correspondence should be addressed: EIB, NCI, National Institutes of Health, 10 Center Dr., Rm. 4B17, Bethesda, MD 20892. Tel.: 301-451-2104; Fax: 301-496-0887; E-mail: chavakist{at}mail.nih.gov.

3 The abbreviations used are: VEGF, vascular endothelial growth factor; CTGF, connective tissue growth factor; PDGF, platelet-derived growth factor; TGF, transforming growth factor; ECM, extracellular matrix; siRNA, small interfering RNA; HUVEC, human umbilical vein endothelial cells; PBS, phosphate-buffered saline; ELISA, enzyme-linked immunosorbent assay. Back


   ACKNOWLEDGMENTS
 
We thank Y. Mueller and Dr. V. Haxsen for technical assistance, as well as Dr. V. Orlova and Dr. A. Bierhaus for help with siRNA experiments.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Carmeliet, P. (2003) Nat. Med. 9, 653–660[CrossRef][Medline] [Order article via Infotrieve]
  2. Risau, W. (1997) Nature 386, 671–674[CrossRef][Medline] [Order article via Infotrieve]
  3. Winet, H. (1996) Bone 19, 39S–57S[Medline] [Order article via Infotrieve]
  4. Gerber, H.-P., and Ferrara, N. (2000) Trends Cardiovasc. Med. 10, 223–228[CrossRef][Medline] [Order article via Infotrieve]
  5. Olsen, B. R., Reginato, A. M., and Wang, W. (2000) Annu. Rev. Cell Dev. Biol. 16, 191–220[CrossRef][Medline] [Order article via Infotrieve]
  6. Mandracchia, V. J., Nelson, S. C., and Barp, E. A. (2001) Clin. Podiatr. Med. Surg. 18, 55–77[Medline] [Order article via Infotrieve]
  7. Decker, B., Bartels, H., and Decker, S. (1995) Anat. Rec. 242, 310–320[CrossRef][Medline] [Order article via Infotrieve]
  8. Trueta, J., and Little, K. (1960) J. Bone Jt. Surg. Br. 42, 367–376[Medline] [Order article via Infotrieve]
  9. Trueta, J. (1963) J. Bone Jt. Surg. 45B, 402–418
  10. Gerber, H.-P., Vu, T. H., Ryan, A. M., Kowalski, J., Werb, Z., and Ferrara, N. (1999) Nat. Med. 5, 623–628[CrossRef][Medline] [Order article via Infotrieve]
  11. Street, J., Winter, D., Wang, J. H., Wakai, A., McGuiness, A., and Redmont, H. P. (2000) Clin. Orthop. Relat. Res. 378, 224–237[CrossRef][Medline] [Order article via Infotrieve]
  12. Street, J., Bao, M., deGuzman, L., Bunting, S., Peale, F. V., Ferrara, N., Steinmetz, H., Hoeffel, J., Cleland, J. L., Daugherty, A., van Bruggen, N., Redmont, H. P., Carano, R. A. D., and Filvaroff, E. H. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 9656–9661[Abstract/Free Full Text]
  13. Mayr-Wohlfart, U., Waltenberger, J., Hausser, H., Kessler, S., Gunther, K. P., Dehio, C., Puhl, W., and Brenner, R. E. (2002) Bone 30, 472–477[Medline] [Order article via Infotrieve]
  14. Wang, D. S., Miura, M., Demura, H., and Sato, K. (1997) Endocrinology 138, 2953–2962[Abstract/Free Full Text]
  15. Lau, L. F., and Lam, S. C. (1999) Exp. Cell Res. 248, 44–57[CrossRef][Medline] [Order article via Infotrieve]
  16. Yang, P. D., and Lau, F. L. (1991) Cell Growth & Differ. 2, 351–357[Abstract]
  17. Leu, S.-J., Lam, S. C., and Lau, L. F. (2002) J. Biol. Chem. 277, 46248–46255[Abstract/Free Full Text]
  18. Babic, A. M., Kireeva, M. L., Kolesnikova, T. V., and Lau, L. F. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6355–6360[Abstract/Free Full Text]
  19. O'Brien, T. P., and Lau, L. F. (1992) Cell Growth & Differ. 3, 645–654[Abstract]
  20. Wong, M., Kireeva, M. L., Kolesnikova, T. V., and Lau, L. F. (1997) Dev. Biol. 192, 492–508[CrossRef][Medline] [Order article via Infotrieve]
  21. Hadjiargyrou, M., Ahrens, W., and Rubin, C. T. (2000) J. Bone Miner. Res. 15, 1014–1023[CrossRef][Medline] [Order article via Infotrieve]
  22. Pendurthi, U. R., Tran, T. T., Post, M., and Rao, L. V. (2005) Cancer Res. 65, 9705–9711[Abstract/Free Full Text]
  23. Kasperk, C., Helmboldt, A., Börcsök, I., Heuthe, S., Cloos, O., Niethard, F., and Ziegler, R. (1997) Calcif. Tissue Int. 61, 464–473[CrossRef][Medline] [Order article via Infotrieve]
  24. Liegibel, U. M., Sommer, U., Tomakidi, P., Hilscher, U., van den Heuvel, L., Pirzer, R., Hillmeier, J., Nawroth, P., and Kasperk, C. (2002) J. Ex. Med. 196, 1387–1392[Abstract/Free Full Text]
  25. Orlova, V. V., Economopoulou, M., Lupu, F., Santoso, S., and Chavakis, T. (2006) J. Exp. Med. 203, 2703–2714[Abstract/Free Full Text]
  26. Chavakis, T., Kanse, S. M., Yutzy, B., Lijnen, H. R., and Preissner, K. T. (1998) Blood 91, 2305–2312[Abstract/Free Full Text]
  27. Chavakis, T., Cines, D. B., Rhee, J. S., Liang, O. D., Schubert, U., Hammes, H. P., Higazi, A. A., Nawroth, P. P., Preissner, K. T., and Bdeir, K. (2004) FASEB J. 18, 1306–1308[Abstract/Free Full Text]
  28. Korff, T., and Augustin, H. G. (1999) J. Cell Sci. 112, 3249–3258[Abstract]
  29. Athanasopoulos, A. N., Economopoulou, M., Orlova, V. V., Sobke, A., Schneider, D., Weber, H., Augustin, H. G., Eming, S. A., Schubert, U., Linn, T., Nawroth, P. P., Hussain, M., Hammes, H. P., Herrmann, M., Preissner, K. T., and Chavakis, T. (2006) Blood 107, 2720–2727[Abstract/Free Full Text]
  30. Barcelos, L. S., Talvani, A., Teixeira, A. S., Vieira, L. Q., Cassali, G. D., Andrade, S. P., and Teixeira, M. M. (2005) J. Leukocyte Biol. 78, 352–358[Abstract/Free Full Text]
  31. Shimoaka, T., Kamekura, S., Chikuda, H., Hoshi, K., Chung, U. I., Akune, T., Maruyama, Z., Komori, T., Matsumoto, M., Ogawa, W., Terauchi, Y., Kadowaki, T., Nakamura K., and Kawaguchi, H. (2004) J. Biol. Chem. 279, 15314–15322[Abstract/Free Full Text]
  32. O'Brien, T. P., Yang, G. P., Sanders, L., and Lau, L. F. (1990) Mol. Cell. Biol. 10, 3569–3577[Abstract/Free Full Text]
  33. Kireeva, M. L., Latinkic, B. V., Kolesnikova, T. V., Chen, C. C., Yang, G. P., Abler, A. S., and Lau, L. F. (1997) Exp. Cell Res. 233, 63–77[CrossRef][Medline] [Order article via Infotrieve]
  34. Kireeva, M. L., Mo, F.-E., Yang, G. P., and Lau, L. F. (1996) Mol. Cell. Biol. 16, 1326–1334[Abstract]
  35. Carano, R. A. D., and Filvaroff, E. H. (2003) Drug Discov. Today 8, 980–989[CrossRef][Medline] [Order article via Infotrieve]
  36. Peng, H., Wright, V., Usas, A., Gearhart, B., Shen, H. C., Cummins, J., and Huard, J. (2002) J. Clin. Investig. 110, 751–759[CrossRef][Medline] [Order article via Infotrieve]
  37. Zhou, D., Herrick, D. J., Rosenbloom, J., and Chaqour, B. (2005) J. Appl. Physiol. 98, 2344–2354[Abstract/Free Full Text]
  38. Haigh, J. J., Gerber, H. P., Ferrara, N., and Wagner, E. F. (2000) Development (Camb.) 127, 1445–1453[Abstract]
  39. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T., and Shibuya, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9349–9354[Abstract/Free Full Text]
  40. Midy, V., and Plouet, J. (1994) Biochem. Biophys. Res. Commu. 199, 380–386[CrossRef][Medline] [Order article via Infotrieve]
  41. Zelzer, E., McLean, W., Ng, Y. S., Fukai, N., Reginato, A. M., Lovejoy, S., D'Amore, P. A., and Olsen, B. R. (2002) Development (Camb.) 129, 1893–1904[Medline] [Order article via Infotrieve]
  42. Radke, S., Battmann, A., Jatzke, S., Eulert, J., Jakob, F., and Schutze, N. (2006) J. Orthop. Res. 24, 945–952[CrossRef][Medline] [Order article via Infotrieve]
  43. Mo, F. E., Muntean, A. G., Chen, C. C., Stolz, D. B., Watkins, S. C., and Lau, L. F. (2002) Mol. Cell. Biol. 22, 8709–8720[Abstract/Free Full Text]
  44. Brigstock, D. R. (2002) Angiogenesis 5, 153–165[CrossRef][Medline] [Order article via Infotrieve]
  45. Si, W., Kang, Q., Luu, H. H., Park, J. K., Luo, Q., Song, W. X., Jiang, W., Luo, X., Li, X., Yin, H., Montag, A. G., Haydon, R. C., and He, T. C. (2006) Mol. Cell. Biol. 26, 2955–2964[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
J.-J. You, C.-H. Yang, M.-S. Chen, and C.-M. Yang
Cysteine-rich 61, a Member of the CCN Family, as a Factor Involved in the Pathogenesis of Proliferative Diabetic Retinopathy
Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3447 - 3455.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H.-W. Koon, D. Zhao, H. Xu, C. Bowe, A. Moss, M. P. Moyer, and C. Pothoulakis
Substance P-Mediated Expression of the Pro-Angiogenic Factor CCN1 Modulates the Course of Colitis
Am. J. Pathol., August 1, 2008; 173(2): 400 - 410.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/37/26746    most recent
M705200200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Athanasopoulos, A. N.
Right arrow Articles by Chavakis, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Athanasopoulos, A. N.
Right arrow Articles by Chavakis, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement